FDA approves expanded pediatric indication for t:slim pump

The FDA approved an expanded pediatric indication for the t:slim insulin pump, lowering its indicated age for use in children from those aged at least 12 years to age 6 years, Tandem Diabetes Care announced in a press release.

The t:slim pump is the first and only touchscreen insulin pump cleared by the FDA. The expanded pediatric indication applies to the current t:slim pump features, with no changes to the existing user interface.

“The t:slim Pump has the look and feel of a modern consumer device, which we believe makes it especially well-suited for school-aged children who have grown up in a world of smartphones and tablets,” Kim Blickenstaff, president and chief executive officer of Tandem Diabetes Care, said in the release. “This FDA clearance allows us to share this product with a broader group of children with diabetes and their parents, who we think can benefit greatly from our technology.”